President Trump stood in the Oval Office on Monday to announce nine new drug companies joining his pricing push. The list includes Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These firms agreed to match lower prices found in other wealthy nations for their products sold to American patients. This move brings the total number of companies in the program to 26.
According to reports, these new deals now cover nearly 90 percent of the entire branded drug market in the United States. RedState reported that the agreements ensure every state Medicaid program gets access to these lower prices. The goal is to stop Americans from paying three times more than patients in other countries for the same medicine.
.@POTUS announces a major expansion of his Most Favored Nation drug pricing initiative — with nine new pharmaceutical companies committing to deliver their lowest drug prices for American patients. pic.twitter.com/hNoPACjnVk
— Rapid Response 47 (@RapidResponse47) August 31, 2026
The new agreements target medicines for serious conditions like Parkinson’s disease, hemophilia, and various forms of cancer. They also cover treatments for macular degeneration, glaucoma, liver disease, and common skin conditions. Health and Human Services Secretary Robert F. Kennedy Jr. highlighted the reach of the expansion during the announcement.
We have now secured agreements with 26 companies in total, according to the day’s developments. Kennedy stated that these pacts encompass nine of the 10 drugs utilized by Americans. The White House also confirmed that any new medicines these companies launch in the future will fall under the same pricing rules. President Trump noted that people have tried to get this done for decades without success.
Beyond just lowering prices, the nine new firms promised a massive boost to domestic manufacturing. Breitbart reported that the companies committed a collective $19.6 billion for U.S. production facilities. Some firms are also donating key ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to ensure the nation has a steady supply.
.@SecKennedy: “Today brings us to a total of 26 companies that have now made agreements with us. These agreements cover nine out of ten drugs that are used by Americans.” https://t.co/sy3VxBS1jF pic.twitter.com/fQMMRO9sdu
— Rapid Response 47 (@RapidResponse47) August 31, 2026
UCB will contribute 163 tons of levetiracetam, a drug used to control seizures. Sun Pharma is donating 71.4 tons of clindamycin and 6.75 tons of doxycycline to treat bacterial infections. Teva Pharmaceuticals will provide 45 metric tons of metronidazole and 4.8 tons of amlodipine. Astellas is contributing 25 kg of tacrolimus to prevent organ rejection in transplant patients. These specific donations help fill the national reserve with vital antibiotics and other critical drugs.
These nine deals mark the 18th through 26th agreements secured since last fall. Other major firms like Eli Lilly, Novo Nordisk, Merck, and Johnson & Johnson have already signed similar deals. The administration backs these agreements with the threat of 100 percent tariffs on imported drugs that do not comply.
